Insight Molecular Diagnostics (IMDX) Short term Debt (2015 - 2026)

Insight Molecular Diagnostics has disclosed Short term Debt across 12 years of filings, most recently posting $159000.0 for Q1 2026.

• Short term Debt for Q1 2026 came in at $159000.0, down 63.28% year-over-year; the trailing twelve-month figure through Mar 2026 was $159000.0 (down 63.28% YoY), and the FY2025 annual result was $428000.0, up 87.72% from the prior year.
• Short term Debt came in at $159000.0 for Q1 2026 at Insight Molecular Diagnostics, down from $428000.0 in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $2.3 million in Q4 2023 to a low of $109000.0 in Q3 2022.
• The 5-year median for Short term Debt is $428000.0 (2025), against an average of $513266.7.
• Across the five-year window, Short term Debt sank 94.81% in 2022 and surged 2022.94% in 2023, its largest moves.
• Insight Molecular Diagnostics' Short term Debt stood at $109000.0 in 2022, then soared by 2022.94% to $2.3 million in 2023, then tumbled by 90.15% to $228000.0 in 2024, then surged by 87.72% to $428000.0 in 2025, then tumbled by 62.85% to $159000.0 in 2026.
• The last three Short term Debt figures came in at $159000.0 (Q1 2026), $428000.0 (Q4 2025), and $1.1 million (Q3 2025), per Business Quant data.